Anti-Bcl10 Antibody [SN74-04]

HUABIO

Anti-Bcl10 Antibody [SN74-04]

7

ImmunoFluorescence, ImmunoPrecipitation, Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin

WB,IF-Cell,IF-Tissue,IHC-P,IP

Research Use Only

Monoclonal

SN74-04

1 mg/ml

Unconjugated

BCL10

BCL10 immune signaling adaptor

CARMEN, CIPER, CLAP, IMD37, c-E10, mE10, B-cell lymphoma/leukemia 10, B cell CLL/lymphoma 10, CARD containing molecule enhancing NF-kB, CARD-containing apoptotic signaling protein, CARD-containing molecule enhancing NF-kappa-B, CARD-containing proapoptotic protein, CED-3/ICH-1 prodomain homologous E10-like regulator, cCARMEN, caspase-recruiting domain-containing protein, cellular homolog of vCARMEN, cellular-E10, hCLAP, mammalian CARD-containing adapter molecule E10

Rabbit

IgG

B-cell lymphoma/leukemia 10

Bcl10, also designated CIPER, c-CARMEN and mE10, was first identified as a gene truncated or mutated in MALT B cell lymphomas and other tumor types. Bcl10 is homologous to the equine herpesvirus-2 E10 gene and, like E10, it contains an N-terminal caspase recruitment domain (CARD). Expression of Bcl10 has been shown to induce NFkappaB activation in a NIK-dependent pathway, and research indicates that the CARD domain is essential for this activation; although in a separate study, Bcl10 by itself did not induce JNK or NFkappaB activation. Overexpression of Bcl10 has been shown to induce apoptosis in a manner dependent on CARD-mediated oligomerization. Bcl10 has also been shown to play a role in processing of caspase-9 to its active dimer. Other studies have shown that Bcl10 is not mutated in many human tumors and lymphomas.

Human

Human

-20°C,2°C to 8°C

41116161